Inspira Technologies Oxy B.H.N. Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) develops, manufactures and markets innovative respiratory support and diagnostic technologies as alternatives to invasive mechanical ventilation for patients with acute respiratory failure; its core products include the U.S. FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass procedures and ECMO internationally, the next-generation INSPIRA ART500 designed to oxygenate blood while patients remain awake and spontaneously breathing, the HYLA real-time continuous non-invasive blood sensor for monitoring key parameters like oxygen saturation and alerting clinicians to condition changes, and the ALICE cardio-pulmonary bypass device. Founded in 2018 and headquartered in Ra'anana, Israel, the company targets the $19 billion mechanical ventilation market serving approximately 20 million annual intensive care patients globally, with operations focused on North America, Europe, Asia Pacific, Latin America, the Middle East and Africa through distribution agreements and OEM partnerships including an exclusive manufacturing deal with Terumo Cardiovascular. Recent developments encompass a October 2025 strategic alliance with Bites Learning Ltd. to embed AI-powered training, simulations and analytics into future INSPIRA ART100 and HYLA systems for enhanced hospital onboarding and compliance; a December 2025 expansion of blood laboratory capabilities to accelerate next-generation sensor and analysis technologies; activation of a U.S. consulting firm in July 2025 to pursue high-value transactions and commercial growth following major purchase orders totaling $49 million from African health authorities; and ongoing clinical integrations in top U.S. hospitals alongside a growing patent portfolio featuring granted U.S. patents for VORTX oxygenation, dual lumen cannula and initiation modules.
QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston
QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials
QTREX in Advanced Discussions with Top-Five Global Quantum Computing Company Regarding Strategic Collaboration
Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity
NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
Inspira Secures $596,000 AME System Order from Leading Irish Technological University
Inspira and Qarakal Sign Joint Development Agreement for Cryogenic Interconnects in Superconducting Quantum Systems
Inspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University
Inspira Technologies (IINN) Falls After-Hours — What's Going On?
Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity
Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion
Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies
Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform
Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension
Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State